Juno Therapeutics, Inc.
Juno Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology. Juno is renowned for its pioneering work in CAR T-cell therapy, which harnesses the body’s immune system to target and eliminate cancer cells. This unique approach has led to groundbreaking treatments that have transformed patient outcomes in certain blood cancers. With a strong market position, Juno Therapeutics has achieved notable milestones, including successful clinical trials and partnerships that enhance its research capabilities. The company continues to push the boundaries of cancer treatment, striving to deliver life-changing therapies to patients worldwide.
DitchCarbon Score
How does Juno Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Juno Therapeutics, Inc.'s score of 15 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Juno Therapeutics, Inc.'s reported carbon emissions
As of 2023, Juno Therapeutics, Inc. has not disclosed specific carbon emissions data, including Scope 1, 2, or 3 emissions. The company has not reported any significant reduction targets or initiatives related to carbon emissions. In the previous years, Juno's emissions data remains unspecified, with no concrete figures available for 2022 and 2021 either. The lack of disclosed emissions data suggests that Juno Therapeutics may still be in the early stages of developing a comprehensive climate strategy. While the company has not committed to specific reduction targets or initiatives, it is essential for organisations in the biotechnology sector to establish clear climate commitments to align with industry standards and expectations. As climate change continues to be a pressing global issue, Juno Therapeutics may need to enhance its transparency and accountability regarding carbon emissions and sustainability efforts in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Juno Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
